Friday, 16 October 2026European Markets

CATERPILLAR INC Stock Bullish Momentum With A 9.25% Jump On Monday

Loading stream...

(vianews) - the market ended the session with caterpillar inc (catr.pa) rising 9.25% to €307.00 on monday while cac 40 slid 0.03% to €7,589.96.

caterpillar inc's last close was €281.00, 1.44% higher than its 52-week high of €277.00.

about caterpillar inc

caterpillar inc. manufactures and sells construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives in the united states and internationally. its construction industries segment offers asphalt pavers, compactors, road reclaimers, forestry machines, cold planers, material handlers, tractors, excavators, telehandlers, motor graders, and pipelayers; compact track and multi-terrain, wheel, track-type, backhoe, and skid steer loaders; and related parts and tools. the company's resource industries segment provides electric rope and hydraulic shovels, draglines, rotary drills, hard rock vehicles, tractors, mining trucks, longwall miners, wheel loaders, off-highway and articulated trucks, wheel tractor scrapers and dozers, fleet management products, landfill and soil compactors, machinery components, autonomous ready vehicles and solutions, work tools, and safety services and mining performance solutions, as well as related parts and services. its energy & transportation segment offers reciprocating engine powered generator sets; reciprocating engines, drivetrain, and integrated systems and solutions; turbines, centrifugal gas compressors, and related services; and diesel-electric locomotives and components, and other rail-related products. the company's financial products segment provides operating and finance leases, installment sale contracts, repair/rebuild financing services, working capital loans, and wholesale financing; and insurance and risk management products and services. its all other operating segment offers filters and fluids, undercarriage, ground engaging tools, fluid transfer products, precision seals, and rubber sealing and connecting components; parts distribution; integrated logistics solutions and distribution services; brand management and marketing strategy services; and digital investments services. caterpillar inc. was founded in 1925 and is headquartered in irving, texas.

earnings per share

as for profitability, caterpillar inc has a trailing twelve months eps of €16.21.

pe ratio

caterpillar inc has a trailing twelve months price to earnings ratio of 18.94. meaning, the purchaser of the share is investing €18.94 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.45%.

volatility

caterpillar inc's last week, last month's, and last quarter's current intraday variation average was 4.07%, 0.51%, and 1.85%.

caterpillar inc's highest amplitude of average volatility was 4.07% (last week), 1.44% (last month), and 1.85% (last quarter).

moving average

caterpillar inc's worth is way higher than its 50-day moving average of €246.64 and way higher than its 200-day moving average of €234.85.

more news about caterpillar inc (catr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com